NIH R01 · 2025
Rewiring T cell exhaustion with immune checkpoint blockade therapy
PROJECT SUMMARY The goal of this project is to determine whether it is possible to promote the development and/or maintenance of CD8+ T cells that are essential for anti-tumor responses to PD-1 immune checkpoint blockade (ICB) therapy by targeting PSGL-1 (P-selectin glycoprotein-1). Studies of exhausted CD8 T cells (TEX) with chronic LCMV infection identified that terminally dysfunctional TEX (TTEX) arise by the progressive differentiation of less exhausted cells with the capacity for effector functions, and that these cells derive from stem-cell like, PD-1+ self-renewing cells (TSC) expressing the transcription factor TCF-1. Although not yet as well studied in cancer, the progeny of TSC,…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.
← All labs at Sanford Burnham Prebys Medical Discovery Institute